# US 2024/0390336 A1 · Methods for Preventing Ectopic Brain Mineralization in Alzheimer's Disease and Dementias

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0390336 A1
- Document ID: US20240390336A1
- Status: Published application
- Kind: A1
- Application number: 18/796,446
- Filed: 2024-08-07
- Published: 2024-11-28
- Earliest claimed: 2022-02-11
- Assignees: Tzerma LLC
- Inventors: Erming Tian; Maurizio Zangari
- Web page: https://patentgrep.com/patent/US20240390336A1

## CPC

- A61K 31/429: condensed with heterocyclic ring systems
- A61K 31/662: Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K 31/663: Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C12N 5/0619: {Neurons}
- C12N 2501/73: Hydrolases (EC 3.)
- C12N 2501/999: Small molecules not provided for elsewhere
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Provided herein are methods for preventing biomineralization in brain tissue or neuronal tissue in vivo or in vitro by inhibiting the deposition of hydroxyapatite therein. Also provided are methods for delaying the progression or onset of Alzheimer's disease in a subject and for preventing the development of Alzheimer's disease in a post-traumatic brain injury subject. Contacting the brain tissue or neuronal tissue with or administering to a subject the drugs Levamisole and/or Foscarnet and/or a bisphosphonate inhibits or decreases levels of alkaline phosphatase and calcium and counteracts alpha-glycerophosphate therein to inhibit the activation of spontaneous biomineralization within a brain tissue to decrease or prevent ectopic biomineralization.

## Claims

### Claim 1

A method for inhibiting activation of a spontaneous biomineralization within a brain tissue, comprising:
contacting the brain tissue with a plurality of compounds effective to inhibit a concomitant increase therein of alkaline phosphatase, alpha-glycerophosphate or an acyclic alkane (CnH2n+2) phosphoester salt.

### Claim 2 (depends on 1)

The method of claim 1, wherein the plurality of compounds comprises Levamisol to inhibit the increase of alkaline phosphatase.

### Claim 3 (depends on 1)

The method of claim 1, wherein the plurality of compounds comprises Foscarnet or a bisphosphonate to inhibit the increase of alpha-glycerophosphate or beta-glycerophosphate or an acyclic alkane (CnH2n+2) phosphoester salt.

### Claim 4 (depends on 1)

The method of claim 1, wherein the contacting step is performed in vitro or in vivo.

### Claim 5

A method for preventing ectopic biomineralization in a neuronal tissue, comprising:
inhibiting the deposition of hydroxyapatite within the neuronal tissue, thereby preventing ectopic mineralization therein.

### Claim 6 (depends on 5)

The method of claim 5, wherein the inhibiting step comprises contacting the neuronal tissue with a first drug effective to inactivate alkaline phosphatase therein.

### Claim 7 (depends on 6)

The method of claim 6, wherein the first drug is Levamisole or a pharmaceutically acceptable composition thereof.

### Claim 8 (depends on 6)

The method of claim 6, wherein the inhibiting step further comprises contacting the neuronal tissue with a second drug effective to counteract alpha-glycerophosphate therein.

### Claim 9 (depends on 8)

The method of claim 8, wherein the second drug is Foscarnet or a biphosphonate or a pharmaceutically acceptable composition of each.

### Claim 10 (depends on 8)

The method of claim 8, wherein the second drug contacts the neuronal tissue concurrently with or sequentially to the first drug.

### Claim 11 (depends on 5)

The method of claim 5, wherein the inhibiting step is performed in vivo or in vitro.

### Claim 12 (depends on 11)

The method of claim 11, wherein the inhibiting step is performed in vivo on a subject with Alzheimer's disease or an Alzheimer's disease related dementia.

### Claim 13

A method for delaying onset or progression of Alzheimer's disease and/or related dementias subsequent to traumatic brain injury in a high-risk subject in need thereof, comprising:
obtaining a first biofluid sample from the high-risk subject and a second biofluid sample from a control subject;
measuring a level of alkaline phosphatase in the first biofluid sample and a level of alkaline phosphatase in the second biofluid sample;
comparing the level of alkaline phosphatase in the first biofluid sample with the level of alkaline phosphatase in the second biofluid sample; and
administering a first drug to the subject to inhibit biomineralization in brain tissue therein when the level of alkaline phosphatase in the first biofluid sample is substantially greater than the level of alkaline phosphatase in the second biofluid sample, thereby delaying the onset or the progression of Alzheimer's disease and/or related dementias subsequent to the traumatic brain injury in the high-risk subject.

### Claim 14 (depends on 13)

The method of claim 13, further comprising monitoring the progression of the Alzheimer's disease and/or the related dementias in the high-risk subject after an onset thereof, comprising the steps of:
obtaining after an interval of time a second biofluid sample from the high-risk subject;
measuring the level of alkaline phosphatase in the second biofluid sample;
comparing the level of alkaline phosphatase in the second biofluid sample from the high-risk subject with the level of alkaline phosphatase in the first biofluid sample from the high-risk subject; wherein said level of alkaline phosphatase in the second biofluid sample that is less than or equal to the level of alkaline phosphatase in the first biofluid sample indicates that said first drug is delaying progression of the Alzheimer's disease and/or the related dementias; and
maintaining a regimen of administering the first drug to the high-risk subject.

### Claim 15 (depends on 14)

The method of claim 14, wherein the first drug is Levamisole or a pharmaceutically acceptable composition thereof.

### Claim 16 (depends on 13)

The method of claim 13, further comprising:
measuring a level of alpha-glycerophosphate or an acyclic alkane (CnH2n+2) phosphoester salt in the first biofluid sample and in the second biofluid sample;
comparing the level of the alpha-glycerophosphate or the acyclic alkane (CnH2n+2) phosphoester salt in the first biofluid sample with the level thereof in the second biofluid sample; and
administering a second drug to the high-risk subject when the level of the alpha-glycerophosphate or the acyclic alkane (CnH2n+2) phosphoester salt in the first biofluid sample is substantially greater than the level of alpha-glycerophosphate or an acyclic alkane (CnH2n+2) phosphoester salt in the first biofluid sample.

### Claim 17 (depends on 16)

The method of claim 16, wherein the second drug is Foscarmet, a therapeutically effective amount of a bisphosphonate or a pharmaceutically acceptable composition of each.

### Claim 18 (depends on 13)

The method of claim 13, wherein the biofluid is peripheral blood serum or cerebrospinal fluid.

### Claim 19

A method for diagnosing and treating an onset of Alzheimer's Disease in a subject after a traumatic brain injury thereto, comprising:
a) obtaining a first biofluid sample from the subject after the traumatic brain injury;
b) measuring a level of alkaline phosphatase in the first biofluid sample as a baseline level;
c) obtaining after an interval of time a second biofluid sample from the subject;
d) measuring a level of alkaline phosphatase in the second biofluid sample;
e) comparing the baseline level of alkaline phosphatase with the level of alkaline phosphatase in the second biofluid sample; wherein when the level of alkaline phosphatase in the second biofluid sample is substantially greater than the baseline level of alkaline phosphatase is indicative of the onset of the Alzheimer's Disease; and
f) administering to the subject a therapeutic amount of a drug effective to inhibit an activity of the alkaline phosphatase in brain tissue, thereby diagnosing and treating the onset of Alzheimer's disease in the subject.

### Claim 20 (depends on 19)

The method of claim 19, comprising repeating at intervals steps b) to f).

### Claim 21 (depends on 19)

The method of claim 19, wherein the drug is Levamisole or a pharmaceutically acceptable composition thereof.

### Claim 22 (depends on 19)

The method of claim 19, further comprising administering to the subject another drug therapeutically effective to counteract alpha-glycerophosphate or an acyclic alkane (CnH2n+2) phosphoester salt in the brain tissue or a pharmaceutically acceptable composition thereof.

### Claim 23 (depends on 22)

The method of claim 22, wherein the other drug is Foscarmet, a therapeutically effective amount of a bisphosphonate or a pharmaceutically acceptable composition of each.

### Claim 24 (depends on 19)

The method of claim 19, wherein the biofluid is peripheral blood serum or cerebrospinal fluid.
